A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation

Warren, Whittney; Franco-Palacios, Domingo; King, Christopher S.; Shlobin, Oksana A.; Nathan, Steven D.; Katugaha, Shalika B.; Mani, Haresh; Brown, Anne

doi:10.1016/j.chest.2017.08.020

Cited by 7 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17 ECMO may be cautiously considered for patients not yet listed for lung transplant. 62 In this context, ECMO is generally considered a "bridge to decision," where the decision whether to list a patient has not yet been made. Ideally, the patient has seen a lung transplant physician, has a clear diagnosis, has completed most of the lung transplant evaluation, and is without clear contraindications to lung transplant (►Fig.…”

Section: Patient Selection and Timing Of Initiationmentioning

confidence: 99%

Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant

Stokes

Gannon

Bacchetta

2021

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary technology capable of supporting cardiac and respiratory function in the presence of end-stage lung disease. Initial experiences using ECMO as a bridge to lung transplant (ECMO-BTLT) were characterized by high rates of ECMO-associated complications and poor posttransplant outcomes. More recently, ECMO-BTLT has garnered success in preserving patients' physiologic condition and candidacy prior to lung transplant due to technological advances and improved management. Despite recent growth, clinical practice surrounding use of ECMO-BTLT remains variable, with little data to inform optimal patient selection and management. Although many questions remain, the use of ECMO-BTLT has shown promising outcomes suggesting that ECMO-BTLT can be an effective strategy to ensure that complex and rapidly decompensating patients with end-stage lung disease can be safely transplanted with good outcomes. Further studies are needed to refine and inform practice patterns, management, and lung allocation in this high-risk and fragile patient population.

show abstract

Section: Patient Selection and Timing Of Initiationmentioning

confidence: 99%

Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant

Stokes

Gannon

Bacchetta

2021

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Nevertheless, in the past ten years, an increased prevalence of non-albicans Candida species, including C. parapsilosis, C. glabrata, C. krusei, C. tropicalis, C. sojae, C. auris, and C. ciferrii, has been reported [10][11][12]. Among NAC spp., Candida ciferrii, named in memory of the Italian mycologist Raffaele Ciferri, also known as S. ciferrii or Trichomonascus ciferrii, has gained our attention in the past years as a multi-drug-resistant pathogen able to cause both local and systemic infections [13][14][15]. The C. ciferrii species is a heterothallic ascomycete yeast-like fungus.…”

Section: Introductionmentioning

confidence: 99%

Stephanoascus ciferrii Complex: The Current State of Infections and Drug Resistance in Humans

Cosio,

Pica,

Fontana

et al. 2024

JoF

View full text Add to dashboard Cite

In recent years, the incidence of fungal infections in humans has increased dramatically, accompanied by an expansion in the number of species implicated as etiological agents, especially environmental fungi never involved before in human infection. Among fungal pathogens, Candida species are the most common opportunistic fungi that can cause local and systemic infections, especially in immunocompromised individuals. Candida albicans (C. albicans) is the most common causative agent of mucosal and healthcare-associated systemic infections. However, during recent decades, there has been a worrying increase in the number of emerging multi-drug-resistant non-albicans Candida (NAC) species, i.e., C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. auris, and C. ciferrii. In particular, Candida ciferrii, also known as Stephanoascus ciferrii or Trichomonascus ciferrii, is a heterothallic ascomycete yeast-like fungus that has received attention in recent decades as a cause of local and systemic fungal diseases. Today, the new definition of the S. ciferrii complex, which consists of S. ciferrii, Candida allociferrii, and Candida mucifera, was proposed after sequencing the 18S rRNA gene. Currently, the S. ciferrii complex is mostly associated with non-severe ear and eye infections, although a few cases of severe candidemia have been reported in immunocompromised individuals. Low susceptibility to currently available antifungal drugs is a rising concern, especially in NAC species. In this regard, a high rate of resistance to azoles and more recently also to echinocandins has emerged in the S. ciferrii complex. This review focuses on epidemiological, biological, and clinical aspects of the S. ciferrii complex, including its pathogenicity and drug resistance.

show abstract

“…Stephanoascus ciferrii (also called Candida ciferrii or Trichomonascus ciferrii ) is a heterothallic ascomycetous yeast-like fungus, which is a teleomorph of Candida ciferrii ( de Gentile et al, 1991 ; Warren et al, 2018 ). It has been reported to cause various human infections such as endophthalmitis, intraorbital abscess, systemic mycosis, and otitis media ( Soki et al, 2010 , 2015 ; Agin et al, 2011 ; Danielescu et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Identification and Antifungal Susceptibility Analysis of Stephanoascus ciferrii Complex Species Isolated From Patients With Chronic Suppurative Otitis Media

et al. 2021

View full text Add to dashboard Cite

BackgroundStephanoascus ciferrii is a heterothallic ascomycetous yeast-like fungus. Recently, the concept of S. ciferrii complex has been proposed and it consists of S. ciferrii, Candida allociferrii, and Candida mucifera. We aimed to identify 32 strains of S. ciferrii complex isolated from patients with chronic suppurative otitis media (CSOM) at the species level and analyze the morphology and antifungal susceptibility profiles of the three species.MethodThe sequencing of the internal transcribed spacer (ITS) region and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) were used to identify S. ciferrii complex species. The SARAMIS software was used for cluster analysis of the mass spectra. All the strains were cultured on Sabouraud dextrose agar (SDA) and CHROM plates for 7 days. In the meantime, colonies of the 32 strains went through Gram staining. The Sensititre YeastOne YO10 colorimetric panel was used for the antifungal susceptibility analysis.ResultsThere were 10 strains of C. allociferrii (31.25%), six strains of C. mucifera (18.75%), and 16 strains of S. ciferrii (50%) in the 32 strains of S. ciferrii complex according to the sequencing of the ITS region. MALDI-TOF MS could identify S. ciferrii but showed no results for C. allociferrii and C. mucifera. The cluster analysis of the mass spectra by SARAMIS indicated that the MALDI-TOF MS could distinguish the three species. The morphology characteristics of the three species were similar. As for antifungal susceptibility, S. ciferrii and C. mucifera tended to have high fluconazole MICs compared with C. allociferrii. C. mucifera and C. allociferrii had relatively low flucytosine MICs while S. ciferrii owned high flucytosine MICs. Besides, C. mucifera tended to have a higher MIC value than S. ciferrii for amphotericin B and C. allociferrii for anidulafungin, micafungin, and caspofungin.ConclusionThe antifungal susceptibility profiles of the three species of S. ciferrii complex had their own characteristics. Besides, more mass spectra of C. allociferrii and C. mucifera are needed to construct the reference database for S. ciferrii complex species, enabling MALDI-TOF MS to identify S. ciferrii complex at species level.

show abstract

A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation

Cited by 7 publications

References 9 publications

Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant

Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant

Stephanoascus ciferrii Complex: The Current State of Infections and Drug Resistance in Humans

Identification and Antifungal Susceptibility Analysis of Stephanoascus ciferrii Complex Species Isolated From Patients With Chronic Suppurative Otitis Media

Contact Info

Product

Resources

About